News

Natco Pharma announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (Adcock Ingram), a leading South African pharmaceutical and healthcare company. With the completion of this transaction, NATCO`s shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary, NATCO`s wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around Rs 1,060 crore at the transaction exchange rate. NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram`s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.

Net profit of Natco Pharma declined 34.11% to Rs 267.90 crore in the quarter ended March 2026 as against Rs 406.60 crore during the previous quarter ended March 2025. Sales declined 39.47% to Rs 739.10 crore in the quarter ended March 2026 as against Rs 1221.00 crore during the previous quarter ended March 2025.For the full year,net profit declined 24.76% to Rs 1418.50 crore in the year ended March 2026 as against Rs 1885.40 crore during the previous year ended March 2025. Sales declined 7.93% to Rs 4078.30 crore in the year ended March 2026 as against Rs 4429.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales739.101221.00 -39 4078.304429.50 -8 OPM %17.2644.89 -35.2249.58 - PBDT194.50604.20 -68 1697.402526.60 -33 PBT144.10505.90 -72 1490.802291.40 -35 NP267.90406.60 -34 1418.501885.40 -25 Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 29 May 2026.

NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry. NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February`26 for multi dose vials and pen device based on the clinical comparison study. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi dose vials will be launched at MRP of INR 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of INR 1,750 for 8mg/3ml. Pen device will be priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April`26. NATCO is the first company to offer generic Semaglutide in multi dose vials with customised syringes. NATCO is also offering the product to third parties for co-marketing. Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 24 March 2026.Powered by Capital Market - Live News